New Nordic Healthbrands (NNH) Q3 2025 earnings summary

Executive summary

• Net sales increased by 7.2% in SEK (9.3% in local currencies) to 139.0 MSEK in Q3 2025 compared to Q3 2024, and by 6.3% to 425.8 MSEK for the first nine months year-over-year.

• Operating profit rose to 2.7 MSEK in Q3 (0.3 MSEK last year) and to 11.4 MSEK for the nine months (-5.4 MSEK last year).

• Profit after tax improved to 1.4 MSEK in Q3 (-1.8 MSEK last year) and 6.2 MSEK for the nine months (-9.6 MSEK last year).

• Growth was driven by successful new product launches and strong performance in Europe, especially the UK.

Financial highlights

• Gross margin decreased to 65.1% in Q3 (66.4% last year) and 64.8% for the nine months (65.1% last year).

• EBITDA for Q3 was 3.4 MSEK (0.8 MSEK last year); for nine months, 13.3 MSEK (-3.8 MSEK last year).

• Cash flow from operating activities was 2.6 MSEK in Q3 (-0.9 MSEK last year) and -0.2 MSEK for nine months (-16.6 MSEK last year).

• Equity increased to 102.5 MSEK (97.6 MSEK last year); equity ratio at 40.1% (40.7% last year).

Outlook and guidance

• Continued focus on profitable growth, product innovation, and expanding distribution in existing and new markets.

• Expectation of growth in the Nordic region with upcoming product launches; strong outlook for Europe and North America.

• Long-term market trend for dietary supplements remains positive, with global demand expected to rise.